Moffitt Treats First Clinical Trial Patient With Gamma Delta CAR T for Bone Metastatic Prostate Cancer
April 17, 2024
April 17, 2024
TAMPA, Florida, April 17 (TNSres) -- Moffitt Cancer Center issued the following news release:
Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone. Roughly 90% of men with advanced prostate cancer will develop bone metastases. The disease significantly impacts patients, causing extreme bo . . .
Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone. Roughly 90% of men with advanced prostate cancer will develop bone metastases. The disease significantly impacts patients, causing extreme bo . . .